1.1 GSK2118436 GlaxoSmithKline In Phase I for solid tumors NCT00880321 BRAF 1.1 PLX4032 Roche In clinical development for melanoma NCT00405587 BRAF 1.1 PLX4032 Roche In clinical development for melanoma NCT00949702 BRAF 1.1 PLX4032 Roche In clinical development for melanoma NCT01006980 BRAF 1.1 RAF265 Novartis In Phase I for malignant melanoma NCT00304525 ARAF 1.1 RAF265 Novartis In Phase I for malignant melanoma NCT00304525 BRAF 1.1 RAF265 Novartis In Phase I for malignant melanoma NCT00304525 CRAF 1.1 RAF265 Novartis In Phase I for malignant melanoma NCT00304525 VEGFR-2 1.1 Sorafenib Bayer Approved for liver and kidney cancer - RAF 1.1 Sorafenib Bayer Approved for liver and kidney cancer - PDGF 1.1 Sorafenib Bayer Approved for liver and kidney cancer - VEGF2/3 1.1 Sorafenib Bayer Approved for liver and kidney cancer - C-Kit and Raf/Mek/ERK pathway 1.1 Sorafenib/ Nexavar Bayer Approved for liver and kidney cancer - RAF 1.1 Sorafenib/ Nexavar Bayer Approved for liver and kidney cancer - PDGF 1.1 Sorafenib/ Nexavar Bayer Approved for liver and kidney cancer - VEGF2/3 1.1 Sorafenib/ Nexavar Bayer Approved for liver and kidney cancer - C-Kit and Raf/Mek/ERK pathway 1.1 XL281 Exelixis In Phase I for solid tumors NCT00451880 RAF 1.1 AZD6244/ ARRY-142886 AstraZeneca colorectal NCT00338130 MEK 1.1 AZD6244/ ARRY-142886 AstraZeneca colorectal NCT00936221 MEK 1.1 AZD6244/ ARRY-142886 AstraZeneca colorectal NCT00866177 MEK 1.1 AZD6244/ ARRY-142886 AstraZeneca colorectal NCT00600496 MEK 1.1 AZD6244/ ARRY-142886 AstraZeneca colorectal NCT00888134 MEK 1.1 AZD6244/ ARRY-142886 AstraZeneca colorectal NCT01021748 MEK 1.1 AZD8330 AstraZeneca In Phase I for advanced malignancies NCT00454090 MEK 1.1 GSK1120212 GlaxoSmithKline melanoma; In phase I for solid tumors/ lymphoma NCT00687622 MEK 1.1 GSK1120212 GlaxoSmithKline melanoma; In phase I for solid tumors/ lymphoma NCT00955773 MEK 1.1 GSK1120212 GlaxoSmithKline melanoma; In phase I for solid tumors/ lymphoma NCT01037127 MEK 1.1 GSK1120212 GlaxoSmithKline melanoma; In phase I for solid tumors/ lymphoma No NCT yet, GSK Protocol ID 114091 MEK 1.1 RDEA119 Ardea Biosciences In Phase I for advanced cancer NCT00610194 MEK 1.1 RDEA119 Ardea Biosciences In Phase I for advanced cancer NCT00785226 MEK 1.1 RO4987655 Roche In Phase I with advanced solid tumors NCT00817518 MEK 1.1 XL518 Genentech In Phase I for solid tumors NCT00996892 MEK 1.1 XL518 Genentech In Phase I for solid tumors NCT00467779 MEK 1.1 AT13387 Astex In Phase I for solid tumors NCT00878423 Hsp90 1.1 Tanespimycin Kosan Biosciences Completed Phase II (NCT00087386) for melanoma patients with stage II or IV cancer - Hsp90 2.1 Dasatinib Bristol-Myers Squibb Approved for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) NCT01092728 C-KIT 2.1 Dasatinib Bristol-Myers Squibb Approved for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) NCT00436605 C-KIT 2.1 Dasatinib Bristol-Myers Squibb Approved for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) NCT00700882 C-KIT 2.1 Dasatinib Bristol-Myers Squibb Approved for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) NCT00597038 C-KIT 2.1 Dasatinib Bristol-Myers Squibb Approved for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) NCT00792545 C-KIT 2.1 Gleevec Novartis positive GIST NCT00424515 C-KIT 2.1 Gleevec Novartis positive GIST NCT00470470 C-KIT 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00631618 C-KIT 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00577382 PDGFR-alpha 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00859326 PDGFR-beta 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00631618 VEGFR1 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00577382 VEGFR2 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00859326 VEGFR3 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00631618 FLT3 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00577382 CSF-1R 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00859326 RET 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00631618 C-KIT 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00577382 PDGFR-alpha 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00859326 PDGFR-beta 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00631618 VEGFR1 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00577382 VEGFR2 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00859326 VEGFR3 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00631618 FLT3 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00577382 CSF-1R 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00859326 RET 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00631618 C-KIT 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00577382 PDGFR-alpha 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00859326 PDGFR-beta 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00631618 VEGFR1 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00577382 VEGFR2 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00859326 VEGFR3 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00631618 FLT3 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00577382 CSF-1R 2.1 Sutent Pfizer Approved for advanced kidney cancer and Gleevec-resistant GIST NCT00859326 RET 2.1 Tasigna Novartis Approved for drug-resistant Chronic Myeloid Leukemia (CML) NCT00788775 C-KIT 5.1 Mocetinostat Methylgene Completed/ terminated trials - HDAC1 5.1 Mocetinostat Methylgene Completed/ terminated trials - HDAC2 5.1 Mocetinostat Methylgene Completed/ terminated trials - HDAC3 5.1 Mocetinostat Methylgene Completed/ terminated trials - HDAC11 5.1 Panobinostat Novartis In Phase II/III for lymphoma and leukemia; In Phase II for prostate cancer, neuroendocrine tumors, breast cancer, brain tumors NCT00925132 HDAC 5.1 Panobinostat Novartis In Phase II/III for lymphoma and leukemia; In Phase II for prostate cancer, neuroendocrine tumors, breast cancer, brain tumors NCT01065467 HDAC 5.1 Valproic acid Abbott Laboratories Approved for epilepsy and bipolar disorder; In clinical trials for several cancers NCT00495872 HDAC1 5.1 Valproic acid Abbott Laboratories Approved for epilepsy and bipolar disorder; In clinical trials for several cancers NCT00996060 HDAC1 5.1 Vorinostat Merck Approved for T-cell lymphoma, in Phase II for many cancers NCT00667082 HDAC 6 BEZ235 Novartis In Phase I for Advanced Solid Malignancies Including Patients With Advanced Breast Cancer NCT00620594 PI3K 6 BGT226 Novartis In Phase I/II for advanced solid malignancies and breast cancer NCT00600275 PI3K 6 GDC0941 Genentech In Phase I for NSCLC, breast cancer, solid tumors, non-Hodgkin's lymphoma etc. NCT00876109 PI3K 6 GDC0941 Genentech In Phase I for NSCLC, breast cancer, solid tumors, non-Hodgkin's lymphoma etc. NCT00876122 PI3K 6 PX-866 Oncothyreon In Phase I for advanced solid tumors NCT00726583 PI3K 6 SF1126 Semafore Pharmaceuticals In Phase I for advanced or metastatic tumors NCT00658671 PI3K 6 SF1126 Semafore Pharmaceuticals In Phase I for advanced or metastatic tumors NCT00658671 MTOR1 6 SF1126 Semafore Pharmaceuticals In Phase I for advanced or metastatic tumors NCT00658671 MTOR2 6 XL147 Exelixis In Phase I for solid tumors; in Phase 1 with Paclitaxel and Carboplatin for Solid Tumors; In Phase I with Erlotinib for Solid Tumors NCT00486135 PI3K 6 XL147 Exelixis In Phase I for solid tumors; in Phase 1 with Paclitaxel and Carboplatin for Solid Tumors; In Phase I with Erlotinib for Solid Tumors NCT00692640 PI3K 6 GSK690693 GlaxoSmithKline Phase I in solid tumor or lymphoma was terminated - AKT 6 MK2206 Merck In development for solid tumors NCT00848718 AKT 6 MK2206 Merck In development for solid tumors NCT00670488 AKT 6 MK2206 Merck In development for solid tumors NCT01021748 AKT 6 Triciribine Phosphate Monohydrate VioQuest In Phase I for advanced hematologic malignancies and metastatic cancer NCT00363454 AKT 6 VQD-002 VioQuest In Phase I for advanced hematologic malignancies and metastatic cancer NCT00363454 AKT 6 AZD8055 AstraZeneca In Phase II/I for advanced tumors and liver cancer NCT00973076 MTOR 6 AZD8055 AstraZeneca In Phase II/I for advanced tumors and liver cancer NCT00731263 MTOR 6 Everolimus Wyeth Approved as an immunosuppresant though used off-label for cancer NCT00703170 MTOR 6 Everolimus Wyeth Approved as an immunosuppresant though used off-label for cancer NCT00703625 MTOR 6 Everolimus Wyeth Approved as an immunosuppresant though used off-label for cancer NCT00375245 MTOR 6 OSI-027 OSI In Phase I for advanced solid tumors/ lymphoma NCT00698243 MTOR 6 Sirolimus Wyeth Approved as an immunosuppresant though used off-label for cancer NCT00703170 MTOR 6 Sirolimus Wyeth Approved as an immunosuppresant though used off-label for cancer NCT00703625 MTOR 6 Sirolimus Wyeth Approved as an immunosuppresant though used off-label for cancer NCT00375245 MTOR 6 Temsirolimus Wyeth Approved for renal cell carcinoma NCT00397982 MTOR 6 Temsirolimus Wyeth Approved for renal cell carcinoma NCT00281957 MTOR 6 Temsirolimus Wyeth Approved for renal cell carcinoma NCT00349206 MTOR 6 Temsirolimus Wyeth Approved for renal cell carcinoma NCT00112476 MTOR 7 AT-7519 Astex NCT00390117 mTOR 7 Alvocidib Sanofi Aventis NCT00005971 mTOR 7 Alvocidib Sanofi Aventis NCT00003690 mTOR 7 Flavopiridol/ alvocidib/ HMR 1275 Sanofi Aventis NCT00005971 mTOR 7 Flavopiridol/ alvocidib/ HMR 1275 Sanofi Aventis NCT00003690 mTOR 7 P1446A-05 Nicholas Piramal NCT00772876 mTOR 7 P276-00 Nicholas Piramal NCT00835419 mTOR 7 PD-0332991 Pfizer NCT00141297 mTOR 7 R547 Hoffmann- La Roche - mTOR 7 SNS-032/ BMS-387032 Sunesis NCT00292864 mTOR 7 UCN-01 NCI NCT00072189 mTOR 7 ZK 304709/ MTGI Schering AG - mTOR